Format

Send to

Choose Destination
Pigment Cell Melanoma Res. 2019 Oct 30. doi: 10.1111/pcmr.12841. [Epub ahead of print]

Functional analysis of RPS27 mutations and expression in melanoma.

Author information

1
Departments of Pathology, New York University School of Medicine, New York, NY, USA.
2
Interdisciplinary Melanoma Cooperative Group (IMCG), NYU Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
3
Department of Population Health, New York University School of Medicine, New York, NY, USA.
4
Applied Bioinformatics Laboratories, NYU Langone Health, New York, NY, USA.
5
Departments of Urology and Medicine, New York University School of Medicine, New York, NY, USA.
6
The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA.

Abstract

Next-generation sequencing has enabled genetic and genomic characterization of melanoma to an unprecedent depth. However, the high mutational background plus the limited depth of coverage of whole-genome sequencing performed on cutaneous melanoma samples make the identification of novel driver mutations difficult. We sought to explore the somatic mutation portfolio in exonic and gene regulatory regions in human melanoma samples, for which we performed targeted sequencing of tumors and matched germline DNA samples from 89 melanoma patients, identifying known and novel recurrent mutations. Two recurrent mutations found in the RPS27 promoter associated with decreased RPS27 mRNA levels in vitro. Data mining and IHC analyses revealed a bimodal pattern of RPS27 expression in melanoma, with RPS27-low patients displaying worse prognosis. In vitro characterization of RPS27-high and RPS27-low melanoma cell lines, as well as loss-of-function experiments, demonstrated that high RPS27 status provides increased proliferative and invasive capacities, while low RPS27 confers survival advantage in low attachment and resistance to therapy. Additionally, we demonstrate that 10 other cancer types harbor bimodal RPS27 expression, and in those, similarly to melanoma, RPS27-low expression associates with worse clinical outcomes. RPS27 promoter mutation could thus represent a mechanism of gene expression modulation in melanoma patients, which may have prognostic and predictive implications.

KEYWORDS:

RPS27; biomarker; drug resistance; high-throughput sequencing; non-coding; promoter analysis

PMID:
31663663
DOI:
10.1111/pcmr.12841

Supplemental Content

Full text links

Icon for Wiley Icon for NYU School of Medicine
Loading ...
Support Center